Pharmagen to Attend 19th Annual Scientific Meeting of SMSNA
SILVER SPRING, Md., Nov. 13, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen") announces it will be participating at the upcoming Sexual Medicine Society North America (SMSNA) Conference in New Orleans, LA November 21-23, 2013. The SMSNA seeks to identify existing and emerging issues in the field of human sexual function and dysfunction, develop standards and guidelines for sexual medicine research and practice, and produce educational program(s) to bring leading-edge concepts of research, clinical practice, ethics, and politics to health care professionals interested in sexual medicine.
The Company plans to showcase its vision for the future of compounding & Urology compliance. Pharmagen looks forward to promoting its Quality Assurance & Quality Control programs; including its Rapid ScanRDI Technology, full-time compliance team and programs to help Urology practices meet their compliance requirements for office use products.
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. offers innovative solutions to the nations sterile pharmaceutical crisis. With a multi-solution approach, Pharmagen is helping to meet the demand of the health provider market through independent wholesale, compounding, and IT solutions. Nationally focused, Pharmagen is a distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.
Kymanox is a premier technical products and project management services organization. They are experts in providing clientele in the Biotech, Pharma, Device, and Nano industries with engineering, scientific, regulatory, and process operations support.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pharmagen disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Pharmagen, Inc.